Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA508 versus NovoMix-style insulin degludec/aspart (Ryzodeg/Novojia) in adults with type 2 diabetes mellitus
CTR20243037Phase 3Completed
- Sponsor
- Chongqing Chen'an Biopharmaceutical
- Start
- Aug 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Chongqing Chen'an Biopharmaceutical. Started Aug 2024; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20243037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243037.